A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study.

Background: We aimed to evaluate the prediction values of non-invasive models for hepatocellular carcinoma (HCC) development in patients with HBV-related liver cirrhosis (LC) and long-term NA treatment.
Methods: Patients with compensated or decompensated cirrhosis (DC), who achieved long-term virological response, were enrolled. DC and its stages were defined by the complications including ascites, encephalopathy, variceal bleeding, or renal failure. Prediction accuracy of several risk scores, including ALBI, CAMD, PAGE-B, mPAGE-B and aMAP, was compared.
Results: The median follow-up duration was 37 (28-66) months. Among the 229 patients, 9 (9.57%) patients in the compensated LC group and 39 (28.89%) patients in the DC group developed HCC. The incidence of HCC was higher in the DC group ( X ² = 12.478, P < 0.01). The AUROC of ALBI, aMAP, CAMD, PAGE-B and mPAGE-B scores were 0.512, 0.667, 0.638, 0.663, 0.679, respectively. There was no significant difference in AUROC between CAMD, aMAP, PAGE-B and mPAGE-B (all P > 0.05). Univariable analysis showed that age, DC status and platelet were associated with HCC development, and multivariable analysis showed that age and DC status (both P < 0.01) were independent risk factors for HCC development, then Model (Age&#95;DC) was developed and its AUROC was 0.718. Another model, Model (Age&#95;DC&#95;PLT&#95;TBil) consisting of age, DC stage, PLT, TBil was also developed, and its AUROC was larger than that of Model (Age&#95;DC) (0.760 vs . 0.718). Moreover, AUROC of Model (Age&#95;DC&#95;PLT&#95;TBil) was larger than the other five models (all P < 0.05). With an optimal cut-off value of 0.236, Model (Age&#95;DC&#95;PLT&#95;TBil) achieved 70.83% sensitivity, 76.24% specificity.
Conclusion: There is a lack of non-invasive risk scores for HCC development in HBV-related DC, and a new model consisting of age, DC stage, PLT, TBil may be an alternative.
Competing Interests: The authors declare that they have no competing interests.
(© 2023 Mao et al.)